Category: Abbott LaboratoriesSyndicate content

Abbott's earnings take a beating in Q1

April 16, 2014 by Arezu Sarvestani

Abbott Labs' earnings sink more than 30% in its 1st quarter of 2014 as special charges eat up its bottom line.

Abbott's earnings take a beating in Q1

Illinois-based Abbott (NYSE:ABT) managed to beat analysts' expectations for its 1st quarter, even as sales waned and special charges eroded its bottom line.

Abbott closes 3 clinical trials for disappearing drug-eluting coronary stent

April 10, 2014 by Arezu Sarvestani

Healthcare giant Abbott completes enrollment in 3 clinical trials evaluating its novel dissolving, drug-eluting scaffold in patients with blocked heart vessels.

Abbott closes 3 clinical trials of dissappearing drug-eluting stents

Illinois healthcare titan Abbott (NYSE:ABT) closed 3 clinical trials after enrolling about 2,800 patients in studies of the company's dissolving Absorb drug-eluting scaffold.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

March 31, 2014 by Brad Perriello

Seven-year results from Boston Scientific's MADIT-CRT trial show long-term benefits for some patients with mild heart failure.

ACC 2014 Roundup: Study shows long-term benefits for some CRT-D patients

Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific's (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology's annual meeting over the weekend.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Abbott wins FDA nod for Supera peripheral stent

March 28, 2014 by Brad Perriello

Abbott says the FDA granted pre-market approval for its Supera stent for treating peripheral artery disease.

Abbott wins FDA nod for Supera peripheral stent

Abbott (NYSE:ABT) said the FDA granted pre-market approval for its Supera peripheral stent.

Abbott Park, Ill.-based Abbott said the stent is designed to conform to the shape of patients' blood vessels. The FDA approved the Supera device for treating occlusions in the superficial femoral artery and the proximal popliteal artery.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Baxter reveals plans to split pharma, medical products businesses

March 27, 2014 by Brad Perriello

Baxter International says it plans to go the way of rivals Abbott and Covidien in splitting its pharmaceuticals and medical products businesses into separate companies.

Baxter reveals plans to split pharma, medical products businesses

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Diabetes: Abbott recalls blood glucose meters over false readings

March 17, 2014 by Arezu Sarvestani

Abbott Diabetes Care recalls FreeStyle and FreeStyle Flash blood glucose meters users over concerns that the devices may report erroneously low readings.

Updated March 17, 2014, at 4:30 pm. with comments from Abbott.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp